Acer Therapeutics to pause trial of hot flashes drug (updated)

Acer Therapeutics

17/03/2023 13:05

(Adds details, background)
       March 17 (Reuters) - Acer Therapeutics Inc  ACER.O  said
it will pause the trial of its experimental drug to treat
menopausal symptoms that failed to reduce the frequency or
severity of hot flashes in post-menopausal women, sending its
shares down over 40% before the bell. 
    The company said on Friday the drug, osanetant, was found to
be safe and well-tolerated, meeting one of the key goals of the
study, and it will review the trial data.
    Osanetant is under development for treatment of patients
with vasomotor symptoms or hot flashes associated with
menopause, prostate cancer and post-traumatic stress disorder,
the company said in a statement. 
    Acer acquired global licensing rights to the drug from
French drugmaker Sanofi SA  SASY.PA  in 2018. 
    
    

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh
Kuber and Shinjini Ganguli)
 ((Mariam.ESunny@thomsonreuters.com;))